Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: Gynecol Oncol. 2013 Apr 8;130(1):12–18. doi: 10.1016/j.ygyno.2013.04.001

Fig. 2.

Fig. 2

Progression free (PFS) and overall survival (OS) curves for patients randomized to intraperitoneal chemotherapy stratified by residual disease following primary cytoreductive surgery. Median PFS and OS for patients with microscopic residual disease were 43 months and 110 months, respectively.